Moreover, Bcl6 inhibitor FX1 repressed the tumor progression of subcutaneous HNSCC and exhibited a synergized effect with PD-1/PDL-1 ICB. The gene discussed is BCL6; the disease is head and neck squamous cell carcinoma.